New IPF treatment moves ahead after encouraging study results
Building on positive Phase 2 data, Puretech Health plans to launch a Phase 3 trial in the coming months to further test its experimental oral therapy deupirfenidone (LYT-100) in people with idiopathic pulmonary fibrosis (IPF). “We are now advancing this pivotal program with urgency to bring forward a…
